HER-2/NEU (HER2) peptide based vaccine with FLT3 ligand (FL) +/- GM-CSF as an adjuvant.

被引：0
|
作者：
Disis, ML
Rinn, K
Davis, D
Caron, D
Schiffman, K
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Immunex Corp, Seattle, WA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1961
引用
收藏
页码：456A / 456A
页数：1
相关论文
共 50 条
  • [31] Peptide based vaccines for immunization to HER-2/neu, an oncogenic self protein
    Cheever, MA
    Disis, ML
    PATHOLOGIE BIOLOGIE, 1998, 46 (02): : 126 - 126
  • [32] Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice
    Venanzi, F. M.
    Barucca, A.
    Havas, K.
    Capitani, M.
    Provinciali, M.
    Scotti, S.
    Concetti, A.
    VACCINE, 2010, 28 (22) : 3841 - 3847
  • [33] Clinical benefit and safety of boosting the HER2 peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence
    Schneble, Erika
    Berry, John S.
    Trappey, Alfred F.
    Vreeland, Timothy J.
    Clifton, Guy T.
    Ponniah, Sathibalan
    Papamichail, Michael
    Perez, Sonia
    Peoples, George E.
    Mittendorf, Elizabeth A.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 219 (04) : E170 - E170
  • [34] Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients
    Disis, ML
    Goodell, V
    Schiffman, K
    Knutson, KL
    JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (05) : 571 - 578
  • [35] Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients
    Mary L. Disis
    Vivian Goodell
    Kathy Schiffman
    Keith L. Knutson
    Journal of Clinical Immunology, 2004, 24 : 571 - 578
  • [36] Increased Prevalence of HLA-DR3 among Breast Cancer Patients: Implications for Adjuvant Her2/neu Peptide Vaccine Trials
    Olson, M. D.
    Clifton, G. T.
    Mittendorf, E. A.
    Ponniah, S.
    Peoples, G. E.
    Holmes, J. P.
    CANCER RESEARCH, 2010, 70
  • [37] Effect of a novel II-key hybrid HER2/nen peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations
    Clifton, G. T.
    Clive, K. S.
    Patil, R.
    Holmes, J. P.
    Benavides, L. C.
    Gates, J. D.
    Tyler, J.
    Mittendorf, E. A.
    Ponniah, S.
    Peoples, G. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Promoting effect of Antrodia camphorata as an immunomodulating adjuvant on the antitumor efficacy of HER-2/neu DNA vaccine
    Chia-Hsin Huang
    Chia-Che Chang
    Chiu-Mei Lin
    Sin-Ting Wang
    Min-Tze Wu
    Eric I. C. Li
    Hsien-Chang Chang
    Chi-Chen Lin
    Cancer Immunology, Immunotherapy, 2010, 59 : 1259 - 1272
  • [39] Promoting effect of Antrodia camphorata as an immunomodulating adjuvant on the antitumor efficacy of HER-2/neu DNA vaccine
    Huang, Chia-Hsin
    Chang, Chia-Che
    Lin, Chiu-Mei
    Wang, Sin-Ting
    Wu, Min-Tze
    Li, Eric I. C.
    Chang, Hsien-Chang
    Lin, Chi-Chen
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (08) : 1259 - 1272
  • [40] A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+breast cancer
    Salazar, L. G.
    Slota, M.
    Wallace, D.
    Higgins, D.
    Coveler, A. L.
    Dang, Y.
    Childs, J.
    Bates, N.
    Waisman, J.
    Disis, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345